Roche welcomes registration of the first subcutaneous PD-L1 cancer immunotherapy

March 4, 2024 Latest News BioPharma

This is a preview of subscriber content

Subscribe now to continue reading.

Roche country medical director Richard Woodfield said the registration of TECENTRIQ SC is “a critical step in making this first-in-class anti-PD-L1 formulation available for eligible patients." …

Subscribe now to continue reading.

Latest Video

Georgia Forrest

Another potential turning point for immunotherapy access in Australia
February 1, 2026 - Latest News
Sandoz adds to vision care options with the listing of biosimilar
February 2, 2026 - Latest News
PYC’s capital raise marks one of the largest biotech fundraisings in Australian market history
February 2, 2026 - Australian Biotech
An announcement that cost more than the listing, because it would have actually cost something
February 1, 2026 - Latest News
If you're going to pay for reforms, are these the changes you want to pay for?
February 3, 2026 - Latest News

Roche welcomes registration of the first subcutaneous PD-L1 cancer immunotherapy

This is a preview of subscriber content

Latest Video

Most Read

Another potential turning point for immunotherapy access in Australia

Sandoz adds to vision care options with the listing of biosimilar

PYC’s capital raise marks one of the largest biotech fundraisings in Australian market history

An announcement that cost more than the listing, because it would have actually cost something

If you're going to pay for reforms, are these the changes you want to pay for?

New Stories

Medicines Australia calls for Budget action to restore access to innovative medicines

Survey exposes deep gaps in support for Australians living with rare cancers

Juvenile Arthritis Foundation Australia seeks new CEO as Angela McKay steps down

AusBiotech and Medicines Australia unite to accelerate advanced therapies

If you're going to pay for reforms, are these the changes you want to pay for?

Arthritis Australia appoints Louise Hardy as CEO at pivotal moment for national advocacy

AusBiotech urges adoption of national life sciences strategy as global competition intensifies

Sign In

Roche welcomes registration of the first subcutaneous PD-L1 cancer immunotherapy

This is a preview of subscriber content

Latest Video

Most Read

Another potential turning point for immunotherapy access in Australia

Sandoz adds to vision care options with the listing of biosimilar

PYC’s capital raise marks one of the largest biotech fundraisings in Australian market history

An announcement that cost more than the listing, because it would have actually cost something

If you're going to pay for reforms, are these the changes you want to pay for?

Follow Us

New Stories

Medicines Australia calls for Budget action to restore access to innovative medicines

Survey exposes deep gaps in support for Australians living with rare cancers

Juvenile Arthritis Foundation Australia seeks new CEO as Angela McKay steps down

AusBiotech and Medicines Australia unite to accelerate advanced therapies

If you're going to pay for reforms, are these the changes you want to pay for?

Arthritis Australia appoints Louise Hardy as CEO at pivotal moment for national advocacy

AusBiotech urges adoption of national life sciences strategy as global competition intensifies